Development of Nardostachys jatamansi and Withania somnifera Formulation for Treatment of Sleep Disorders

الموضوعات : Journal of Chemical Health Risks

Anjan Adhikari ¹ , Subhadas Chatterjee ² , Moumita Ray ³ , Rania Indu ⁴ , Sangita Bhattacharya ⁵ , Sankhadip Bose ⁶

1 - Medical College Kolkata, 88 College St, College Square, Kolkata-700073, West Bengal, India
2 - Sanaka Educational Trust’s Group of Institutions, Department of Pharmacy, Durgapur, West Bengal, India
3 - Department of Pharmaceutical Technology, JIS University, 81, Nilgunj Road, Agarpara, Kolkata-700109, West Bengal, India
4 - Department of Pharmaceutical Technology, JIS University, 81, Nilgunj Road, Agarpara, Kolkata-700109, West Bengal, India
5 - Department of Clinical research, Micro Labs Limited, 58/3, Kudlu, Bangalore-560068, India
6 - The Neotia University, School of Pharmacy, South 24 Parganas, West Bengal, India

تاريخ الإرسال : 23 الخميس , رجب, 1446 تاريخ التأكيد : 01 السبت , جمادى الثانية, 1447 تاريخ الإصدار : 06 الأحد , ربيع الثاني, 1447

الکلمات المفتاحية: Sleep disorders, Withaferin A, Anxiety, Insomnia, Depression, Catalepsy,

ملخص المقالة :

Sleep is a state of decreased awareness of environmental stimuli that is distinguished from states such as coma or hibernation by its relatively rapid reversibility. Insomnia and other sleeping disorders are quite common in worldwide population nowadays. Although treatment with sedatives and hypnotics are available, still the safety of those medicaments are a big question. In this present study, 2 different formulations developed by Nardostachys jatamansi and Withania somnifera at 2 different proportions are made and evaluated for treatment of several sleep disorders. Isolation of marker compounds, evaluation of Pharmacokinetic parameters and evaluation of the safety and efficacy of those 2 test formulations were performed. From the obtained results, it could be inferred that both the formulations have potential therapeutic properties for prophylaxis and treatment of sleep disorders, along with no signs of toxicity for oral administration and other adverse effects which are associated with the use of traditional sedatives-hypnotics.Sleep is a state of decreased awareness of environmental stimuli, distinguished from states such as coma or hibernation by its relatively rapid reversibility. Insomnia and other sleeping disorders are quite common in the worldwide population nowadays. Although treatment with sedatives and hypnotics is available, the safety of those medications is a big question. In this present study, 2 different formulations developed by Nardostachys jatamansi and Withania somnifera at 2 different proportions are made and evaluated for the treatment of several sleep disorders. Isolation of marker compounds, evaluation of Pharmacokinetic parameters, and evaluation of the safety and efficacy of those 2 test formulations were performed. The results inferred that both formulations have potential therapeutic properties for prophylaxis and treatment of sleep disorders, as both formulations produced more than 50% sleep. Anxiety and cortisone levels were inhibited for more than 30% along with no signs of toxicity for oral administration at a 2g kg^-1 dose, and other adverse effects associated with the use of traditional sedatives-hypnotics. Moreover, a reduction in total neurotransmitter levels in the brain, elevated due to sleep deprivation was also observed when maintaining levels below 50%. From these results, it was concluded that both formulations have a potential activity against sleep-related disorders without potential toxicological effects. 

المصادر:

1. Sharma S., Kavuru M., 2010. Sleep and metabolism: an overview. International Journal of Endocrinology. doi: 10.1155/2010/270832
2. Dzierzewski J.M., Donovan E.K., Kay D.B., Sannes T.S., Bradbrook K.E., 2020. Sleep Inconsistency and Markers of Inflammation. Frontiers in Neurology. doi: 10.3389/fneur.2020.01042. eCollection 2020
3. Garbarino S., Lanteri P., Bragazzi N.L., Magnavita N., Scoditti E., 2021. Role of sleep deprivation in immune-related disease risk and outcomes. Communications Biology. 4, 1304.
4. Mullington J.M., Simpson N.S., Meier-Ewert H.K., Haack M., 2010. Sleep loss and inflammation. Best Practice & Research Clinical Endocrinology & Metabolism. 24,775–84.
5. Liu M.T., Greer D, Maroney M., 2023. Chapter 4 - Side effects of sedatives and hypnotics. Side Effects of Drugs Annual. 45,33–47.
6. Sharma V.D., Mishra R.K., Yadav M.K., Marde R., Joshi S.C., 2024. Nardostachys jatamansi play significant role in Insomnia. International Journal of Pharmacognosy and Life Science. 5(2), 13–7.
7. Bhattacharya S.K., Bhattacharya A., Sairam K., Ghosal S., 2000. Anxiolytic-antidepressant activity of Withania somnifera glycowithanolides: an experimental study. Phytomedicine. 7,463–9.
8. Panchal R., Goswami N.N., Anovadiya A., 2019. Evaluation of antidepressant activity of hydro-alcoholic extract of rhizomes of Nardostachys jatamansi DC per se and in combination with fluoxetine in wistar albino rats and swiss albino mice. International Journal of Basic & Clinical Pharmacology. 9,32–5.
9. Li R., Wang Z.M, Wang Y., Dong X., Zhang L.H., Wang T., Zhu Y., Gao X.M., Wu H.H., Xu Y.T., 2021. Antidepressant activities and regulative effects on serotonin transporter of Nardostachys jatamansi DC. Journal of Ethnopharmacology. 268,113601.
10. Razack S., Kandikattu H.K., Venuprasad M.P., Amruta N., Khanum F., Chuttani K., Mishra A.K., 2018. Anxiolytic actions of Nardostachys jatamansi via GABA benzodiazepine channel complex mechanism and its biodistribution studies. Metabolic Brain Disease. 33(5),1533–49.
11. Jahanbakhsh S.P., Manteghi A.A., Emami S.A., Mahyari S., Gholampour B., Mohammadpour A.H., Sahebkar A., 2016. Evaluation of the efficacy of Withania somnifera (Ashwagandha) root extract in patients with obsessive-compulsive disorder: A randomized double-blind placebo-controlled trial. Complementary Therapies in Medicine. 27, 25–9.
12. CPCSEA., 2003. Cpcsea-Guidlines -All. Cpcsea Guidelines for Laboratory Animal Facility. 35,257–74.
13. Adhikari A., Hazra A., Sur T., 2015. Detection of arecoline by simple high-performance thin-layer chromatographic method in Indian nontobacco pan masala. Journal of Advanced Pharmaceutical Technology and Research. 6(4), 195–9.
14. Ray M., Adhikari A., Sur T.K., Besra S.E., Biswas S., Das A.K., 2016. Evaluation of anti-inflammatory potential of ethanolic extract of the leaves of Rhizophora mucronata, a sunderban mangrove. International Journal of Reserach and Development in Pharmacy and Life Sciences. 6(1), 2506–16.
15. Daniel W.A., Syrek M., Haduch A., Wojcikowski J., 2000. Pharmacokinetics and metabolism of thioridazine during co-administration of tricyclic antidepressants. British Journal of Pharmacology. 131(2),287–95.
16. Sumanth M., Nedunuri S., 2014. Comparison of Bioavailability and Bioequivalence of Herbal Anxiolytic Drugs With Marketed Drug Alprazolam. World Journal of Pharmaceutical Research. 3(10),1358–66.
17. Rouini M.R., Ardakani Y.H., Moghaddam K.A., Solatani F., 2008. An improved HPLC method for rapid quantitation of diazepam and its major metabolites in human plasma. Talanta. 75(3),671–6.
18. OECD., 2002. The Organization of Economic Co-operation and Development Guidelines Test No. 423: Acute Oral toxicity - Acute Toxic Class Method, OECD Guidelines for the Testing of Chemicals, Section 4. Oecd.1–14.
19. Dayan A.D., 1998. Drug Discovery and Evaluation edited by HG Vogel and WH Vogel. Human & Experimental Toxicology. 17(10), 591
20. Abdi-Azar H., Maleki S.A., 2014. Comparison of the anesthesia with thiopental sodium alone and their combination with Citrus aurantium L . (Rutaseae) essential oil in male rat. Bulletin of Environment, Pharmacology and Life Sciences. 3(Special Issue V), 37–44.
21. Lyons D.M., 2009. Animal models. The American Psychiatric Publishing Textbook of Psychopharmacology. Arlington, VA, US: American Psychiatric Publishing, Inc.153–60.
22. Kallman M.J., 2014. Antidepressant Activity. Drug Discovery and Evaluation: Pharmacological Assays. Berlin, Heidelberg: Springer Berlin Heidelberg. 1–101.
23. Lyle N., Gomes A. Sur T., Munshi S. Paul S., Chatterjee S., Bhattacharyya D., 2009. The role of antioxidant properties of Nardostachys jatamansi in alleviation of the symptoms of the chronic fatigue syndrome. Behavioural Brain Research. 202(2), 285–90.
24. Bhattacharya S.K., Bhattacharya A., Sairam K., Ghosal S., 2000. Anxiolytic-antidepressant activity of Withania somnifera glycowithanolides: An experimental study. Phytomedicine. 7(6), 463–9.
25. Pramanik S.S., Sur T.K., Debnath P.K., Bhattacharyya D., 2010. Effect of Pueraria tuberosa tuber extract on chronic foot shock stress in Wistar rats. Nepal Medical College Journal. 12(4), 234–8.
26. Meerlo P., Sgoifo A., Suchecki D., 2008. Restricted and disrupted sleep: Effects on autonomic function, neuroendocrine stress systems and stress responsivity. Sleep Medicine Reviews. 12(3),197–210.
27. Zarcone V.P.J., Benson K.L., Greene K.A. Csernansky J.G., Faull K.F., 1994. The effect of chronic alprazolam on sleep and bioamine metabolites in depression. Journal of Clinical Psychopharmacology. 14(1), 36–40.
28. Ruigt G.S.F., Van Proosdij J.N., Van Delft A.M.L., 1989. A large scale, high resolution, automated system for rat sleep staging. I. Methodology and technical aspects. Electroencephalography and Clinical Neurophysiology. 73(1), 52–63.
29. Chiu C.H., Chyau C.C., Chen C.C., Lee L.Y., Chen W.P., Liu J.L., Lin W.H., Mong M.C., 2018. Erinacine a-enriched Hericium erinaceus mycelium produces antidepressant-like effects through modulating BDNF/PI3K/Akt/GSK-3β signaling in mice. International Journal of Molecular Sciences. 19(341), 1–21.
30. Konstandi M., Johnson E., Lang M.A., Malamas M., Marselos M., 2000. Noradrenaline, dopamine, serotonin: Different effects of psychological stress on brain biogenic amines in mice and rats. Pharmacoligcal Research. 41(3), 341–6.
31. Khisti R.T., Mandhane S.N., Chopde C.T., 1997. Haloperidol-induced catalepsy: a model for screening antidepressants effective in treatment of depression with Parkinson’s disease. Indian Journal of Experimental Biology. 35(12),1297–301.
32. Dunham NW, Miya TS., 1957. A note on a simple apparatus for detecting neurological deficit in rats and mice. Journal of the American Pharmaceutical Association. American Pharmaceutical Association. 46(3), 208–9.
33. Sanger D.J., Depoortere H., 1998. The pharmacology and mechanism of action of zolpidem. CNS Drug Reviews. 4(4), 323–40.
34. Irwin S., 1968. Comprehensive Observational Assessment: Ia. A Systematic, Quantitative Procedure for Assessing the Behavioral and Physiologic State of the Mouse. Psychopharmacologia. 13,222–57.
35. Gauvin D.V., Zimmermann Z.J., Dalton J.A., Baird T.J., Kallman M.J., 2019. CNS Safety Screening Under ICH S7A Guidelines Requires Observations of Multiple Behavioral Units to Assess Motor Function. International Journal of Toxicology. 38(5), 339–56.
36. Maxwell C.R., Spangenberg R.J., Hoek J.B., Silberstein S.D., Oshinsky M.L., 2010. Acetate causes alcohol hangover headache in rats. PLoS One. 5(12),1–9.